Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript
11:03pm, Monday, 04'th Nov 2024
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate A
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
06:31pm, Monday, 04'th Nov 2024
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Monday, 28'th Oct 2024
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
12:15pm, Thursday, 17'th Oct 2024
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
07:00am, Monday, 14'th Oct 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
07:00am, Wednesday, 09'th Oct 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
03:20pm, Tuesday, 08'th Oct 2024
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
12:10pm, Thursday, 03'rd Oct 2024
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
01:30am, Monday, 23'rd Sep 2024
Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfr
Glaukos Stocks Rides on Strong Product Demand Amid Competition
09:32am, Wednesday, 11'th Sep 2024
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
02:40pm, Monday, 09'th Sep 2024
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
02:20pm, Thursday, 22'nd Aug 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
08:01pm, Friday, 02'nd Aug 2024
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
08:35am, Thursday, 01'st Aug 2024
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript
08:57pm, Wednesday, 31'st Jul 2024
Glaukos Corporation (NYSE:GKOS ) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - Pre
